Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ENC-10x-xPTG
- Development stage
- Preclinical
- Lead developer
- Encellin
- Modality
- Cell Therapies
- Administration
- Implant, Subcutaneous
01
Overview
ENC-10x-xPTG is an investigational encapsulated cell therapy being developed by Encellin for the treatment of severe refractory hypoparathyroidism. The therapy utilizes Encellin's proprietary Encapsulated Cell Replacement Therapy (ENCRT) platform, which is designed to protect therapeutic cells from immune rejection and promote vascular integration without requiring chronic immunosuppression. While the exact cell payload for ENC-10x-xPTG is still to be determined (TBD), it is intended to restore parathyroid endocrine function and may potentially utilize xenogeneic parathyroid tissue (PTG). The program is currently in the discovery stage.
Beyond the preview
Go deeper on ENC-10x-xPTG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ENC-10x-xPTG.